NVO
Novo Nordisk A/S
37.30$
-0.2%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 16.5% | 15.2% | 15.2% | 15.1% | 15.9% | 15.2% | 16.5% | 16.7% | 23.9% | 19.1% | 14.0% | 21.8% | 19.4% | |
| 83.5% | 84.8% | 84.8% | 84.9% | 84.1% | 84.8% | 83.5% | 83.3% | 76.1% | 80.9% | 86.0% | 78.2% | 80.6% | |
| 13.8% | 15.9% | 13.2% | 23.8% | 13.3% | 16.1% | 13.2% | 15.2% | 20.5% | 18.5% | 10.6% | 22.7% | 17.6% | |
| 2.1% | 2.2% | 1.8% | 1.7% | 1.9% | 1.8% | 1.6% | 1.7% | 2.5% | 2.0% | 1.2% | 1.7% | 1.8% | |
| 37.6% | 44.2% | 36.1% | 46.8% | 36.7% | 41.9% | 33.8% | 39.8% | 44.5% | 40.8% | 24.4% | 43.7% | 37.5% | |
| 45.8% | 40.6% | 48.7% | 38.1% | 47.4% | 42.9% | 49.7% | 43.5% | 31.6% | 40.1% | 61.6% | 34.5% | 43.1% | |
| 3.7% | 1.4% | 3.2% | 2.3% | 1.2% | 5.9% | 6.6% | 6.5% | 6.7% | 10.9% | 3.6% | 1.9% | 5.7% | |
| 47.8% | 41.9% | 48.8% | 37.2% | 48.2% | 41.5% | 47.4% | 44.0% | 34.0% | 43.2% | 64.2% | 34.2% | 45.2% | |
| 9.5% | 8.6% | 10.0% | 7.8% | 9.9% | 8.6% | 10.2% | 9.5% | 7.4% | 9.2% | 14.1% | 7.5% | 9.8% | |
| 38.3% | 33.3% | 38.9% | 29.5% | 38.3% | 32.9% | 37.2% | 34.5% | 26.7% | 34.0% | 50.2% | 26.7% | 35.3% | |
| 55.8% | 43.3% | 56.5% | 52.5% | 52.4% | 53.5% | 59.0% | 56.7% | 44.4% | 50.2% | 71.5% | 49.3% | 54.9% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.